ArticleFunctional & integrative genomics2026
Exploring the potential targets and mechanisms of artemisinin in the treatment of diabetic kidney disease using network pharmacology and molecular docking.
Article in Functional & integrative genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic kidney disease (DKD) is a secondary glomerular disease caused by diabetes, and its incidence is increasing annually. Artemisinin is an organic compound with multiple pharmacological effects. This study aims to investigate the potential therapeutic effects of artemisinin on DKD and its molecular mechanisms. Common targets were identified using network pharmacology, transcriptome data from the Gene Expression Omnibus (GEO) database, and three machine learning algorithms, including Least Absolute Shrinkage and Selection Operator (LASSO), Support Vector Machine Recursive Feature Elimination (SVM-RFE), and Random Forest (RF). Target expression profiles were examined through single-cell sequencing data analysis. Molecular docking and cellular assays, including western blot, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL), enzyme-linked immunosorbent assay (ELISA), and reactive oxygen species (ROS) detection, validated the effects of artemisinin and Fms related receptor tyrosine kinase 1(FLT1) on human renal glomerular endothelial cells (HRGECs) under a high-glucose (HG) injury model. A total of 64 common targets between artemisinin and DKD were identified, and machine learning identified FLT1 as a key target. Single-cell analysis revealed high FLT1 expression in DKD endothelial cells. More importantly, artemisinin exhibited stable binding to FLT1. HG reduced FLT1 expression and cell viability in HRGECs. Besides, HG-induced decrease in cell viability, increase in proportion of TUNEL-positive cells, elevation in the levels of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) and lipid ROS production were reversed by FLT1 overexpression or artemisinin treatment, and these protective effects of artemisinin were significantly attenuated upon FLT1 knockdown. Artemisinin alleviates HG-induced HRGEC injury by restoring FLT1 expression, providing a potential therapeutic target for DKD treatment.
Indexed as
Identifiers
42223693What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.